Intramuscular fosphenytoin (Cerebyx®) in patients requiring a loading dose of phenytoin Academic Article uri icon


MeSH Major

  • Hospice Care
  • Hospitalists
  • Palliative Care
  • Professional-Family Relations
  • Quality of Health Care


  • Fosphenytoin (Cerebyx), is a water soluble prodrug that is rapidly and completely converted to phenytoin. This study reports the injection-site tolerance and safety of intramuscular fosphenytoin (> 10 mg/kg doses) in 60 patients requiring a phenytoin loading dose. Patients received injections at single or multiple sites with volumes ranging from 4 to 30 ml per injection site. The majority of patients had no irritation (erythema, swelling, tenderness, bruising) or complaints of discomfort related to fosphenytoin injection either after injection (95%) or at follow-up (88%). Irritation, when reported, was mild in all cases. Forty of 60 patients (67%) reported transient side effects, primarily involving the central nervous system, such as nystagmus, dizziness or ataxia, which are commonly associated with phenytoin therapy. All patients received prescribed doses; no patient had an injection(s) stopped due to intolerance or side effects. No serious adverse events occurred with intramuscular fosphenytoin. In this study, intramuscular fosphenytoin was demonstrated to be a safe and well tolerated, and in many instances, a preferable alternative to other means of phenytoin loading.

publication date

  • October 2, 1997



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1016/S0920-1211(97)00054-5

Additional Document Info

start page

  • 181

end page

  • 7


  • 28


  • 3